115 related articles for article (PubMed ID: 7849488)
21. Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery.
Morishita R; Gibbons GH; Kaneda Y; Ogihara T; Dzau VJ
Gene; 1994 Nov; 149(1):13-9. PubMed ID: 7958977
[TBL] [Abstract][Full Text] [Related]
22. The effect of pegylated antisense acetylcholinesterase on hematopoiesis.
Patinkin D; Hidmi A; Weiss L; Slavin S; Katzhendler J
Oligonucleotides; 2003; 13(4):207-16. PubMed ID: 15000836
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of O6-methylguanine-DNA methyltransferase in HeLa S3 cells by antisense oligodeoxynucleotides.
Ballal SK; Isham K; Foote RS
SAAS Bull Biochem Biotechnol; 1994; 7():40-3. PubMed ID: 7765156
[TBL] [Abstract][Full Text] [Related]
24. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase.
Monia BP; Johnston JF; Geiger T; Muller M; Fabbro D
Nat Med; 1996 Jun; 2(6):668-75. PubMed ID: 8640558
[TBL] [Abstract][Full Text] [Related]
25. Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus.
Pisetsky DS; Reich CF
Life Sci; 1994; 54(2):101-7. PubMed ID: 8277816
[TBL] [Abstract][Full Text] [Related]
26. Cellular pharmacology and protein binding of phosphoromonothioate and phosphorodithioate oligodeoxynucleotides: a comparative study.
Tonkinson JL; Guvakova M; Khaled Z; Lee J; Yakubov L; Marshall WS; Caruthers MH; Stein CA
Antisense Res Dev; 1994; 4(4):269-78. PubMed ID: 7537561
[TBL] [Abstract][Full Text] [Related]
27. Anti-sense oligonucleotides directed against EGF-related growth factors enhance anti-proliferative effect of conventional anti-tumor drugs in human colon-cancer cells.
De Luca A; Selvam MP; Sandomenico C; Pepe S; Bianco AR; Ciardiello F; Salomon DS; Normanno N
Int J Cancer; 1997 Oct; 73(2):277-82. PubMed ID: 9335455
[TBL] [Abstract][Full Text] [Related]
28. Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity.
Thierry AR; Dritschilo A
Nucleic Acids Res; 1992 Nov; 20(21):5691-8. PubMed ID: 1454532
[TBL] [Abstract][Full Text] [Related]
29. Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera.
Akhtar S; Kole R; Juliano RL
Life Sci; 1991; 49(24):1793-801. PubMed ID: 1943483
[TBL] [Abstract][Full Text] [Related]
30. Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides.
Agrawal S
Biochim Biophys Acta; 1999 Dec; 1489(1):53-68. PubMed ID: 10806997
[TBL] [Abstract][Full Text] [Related]
31. Effect of different chemically modified oligodeoxynucleotides on immune stimulation.
Zhao Q; Temsamani J; Iadarola PL; Jiang Z; Agrawal S
Biochem Pharmacol; 1996 Jan; 51(2):173-82. PubMed ID: 8615886
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of phage phi 29 assembly by antisense oligonucleotides targeting viral pRNA essential for DNA packaging.
Zhang C; Garver K; Guo P
Virology; 1995 Aug; 211(2):568-76. PubMed ID: 7645260
[TBL] [Abstract][Full Text] [Related]
33. Treatment of the T98G glioblastoma cell line with antisense oligonucleotides directed toward mRNA encoding transforming growth factor-alpha and the epidermal growth factor receptor.
Rubenstein M; Glick R; Lichtor T; Mirochnik Y; Chou P; Guinan P
Med Oncol; 2001; 18(2):121-30. PubMed ID: 11778757
[TBL] [Abstract][Full Text] [Related]
34. A comparison of gag, pol and rev antisense oligodeoxynucleotides as inhibitors of HIV-1.
Kinchington D; Galpin S; Jaroszewski JW; Ghosh K; Subasinghe C; Cohen JS
Antiviral Res; 1992 Jan; 17(1):53-62. PubMed ID: 1736810
[TBL] [Abstract][Full Text] [Related]
35. Na+/Ca2+ exchange in neonatal rat heart cells: antisense inhibition and protein half-life.
Slodzinski MK; Blaustein MP
Am J Physiol; 1998 Aug; 275(2):C459-67. PubMed ID: 9688600
[TBL] [Abstract][Full Text] [Related]
36. Nucleotide pyrophosphatase/phosphodiesterase 1 is responsible for degradation of antisense phosphorothioate oligonucleotides.
Wójcik M; Cieślak M; Stec WJ; Goding JW; Koziołkiewicz M
Oligonucleotides; 2007; 17(1):134-45. PubMed ID: 17461770
[TBL] [Abstract][Full Text] [Related]
37. Antiproliferative effect of c-myc antisense phosphorothioate oligodeoxynucleotides in malignant glioma cells.
Broaddus WC; Chen ZJ; Prabhu SS; Loudon WG; Gillies GT; Phillips LL; Fillmore H
Neurosurgery; 1997 Oct; 41(4):908-15. PubMed ID: 9316053
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of mouse hepatitis virus multiplication by phosphorothioate analogues of oligodeoxynucleotides complementary to the leader RNA.
Hayashi M; Maeda A; Watanabe T; Hanaki K; Arai S; Nozaki S
J Vet Med Sci; 1995 Dec; 57(6):1081-3. PubMed ID: 8720052
[TBL] [Abstract][Full Text] [Related]
39. Antisense c-myc effects on preimplantation mouse embryo development.
Paria BC; Dey SK; Andrews GK
Proc Natl Acad Sci U S A; 1992 Nov; 89(21):10051-5. PubMed ID: 1279668
[TBL] [Abstract][Full Text] [Related]
40. Amplification of antibody production by phosphorothioate oligodeoxynucleotides.
Branda RF; Moore AL; Lafayette AR; Mathews L; Hong R; Zon G; Brown T; McCormack JJ
J Lab Clin Med; 1996 Sep; 128(3):329-38. PubMed ID: 8783641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
